Anticholinergic Burden in a Neurogenic Bladder Three Decades From the Dementia Data
The literature linking bladder anticholinergics to dementia risk was built in patients over 55. A 31-year-old on the same drug for a different reason, and for far longer, doesn't fit that literature either way.
Louis A., a 31-year-old data analyst who has spent the past two years building a reputation at work for catching errors other people miss, was diagnosed with multiple sclerosis at 24 and started oxybutynin for neurogenic detrusor overactivity within the first year of that diagnosis — seven years of continuous daily use, a fact that only became relevant to him personally in the last few months, when he started losing words mid-sentence in exactly the kind of meetings where his reputation for precision used to be the whole point. He mentioned it to his neurologist almost apologetically, framing it as probably nothing, before admitting it had happened three times in the past two weeks alone, each time in front of colleagues.
The large studies linking anticholinergic bladder medications to dementia risk — Coupland et al.'s nested case-control analysis chief among them — were built entirely in adults 55 and older, tracking cumulative exposure against a disease whose baseline risk in that population is already substantial; Louis is 31, with a baseline dementia risk near zero regardless of medication, which makes that literature genuinely silent on whether his own seven years of exposure carries anything like the signal seen in a population three decades older. Welk's narrative review of anticholinergics in neurogenic lower urinary tract dysfunction is the closer fit, and a thinner one: across the whole field it found two studies showing cognitive impairment, one in spinal cord injury and one in multiple sclerosis, and both implicated oxybutynin and tolterodine specifically rather than the class as a whole — the older, more lipophilic agents that cross into the brain most readily. Louis takes oxybutynin. His own numbers are what resist sorting: a mild deficit on word-generation testing against otherwise intact cognition, on a lesion burden unchanged from imaging a year ago. The stable MRI argues against new demyelination driving it, but cognitive symptoms in multiple sclerosis are known not to track lesion burden closely, so his imaging cannot acquit the disease either — it can only decline to convict it.
Neurology-urology joint visit, a new complaint
I'd trial him off oxybutynin before assuming this is MS-related cognitive decline. Seven years of continuous anticholinergic exposure is real, and while the dementia-risk literature was built in a much older population, the mechanism — central muscarinic receptor blockade affecting memory and word retrieval circuits — doesn't obviously require someone to be over 55 to matter; it just hasn't been well studied under 55 because that's not where dementia outcomes get measured.
I want to flag that stopping his bladder control isn't a free trial — it has a real cost if his NDO symptoms return, and I'd want us to be honest that we're extrapolating a mechanism, not applying confirmed evidence at his age.
The Welk review Dr. Okafor is drawing on found two studies in neurogenic patients, not two studies in young ones — and both used exactly the drug he's on, which is real signal, but a signal, not a confirmed finding at 31. I'd support switching him to mirabegron rather than simply stopping anticholinergic therapy outright, since that tests the same hypothesis without leaving him unprotected.
I'd add one more layer neither of you has weighted yet: multiple sclerosis itself causes exactly this kind of word-finding difficulty independent of any medication, and his stable MRI doesn't rule that out — cognitive symptoms in MS don't always track lesion burden closely.
Switching to mirabegron, as Dr. Reyes suggests, actually serves both hypotheses at once: if his word-finding improves off oxybutynin, that's real evidence toward drug burden; if it doesn't, we haven't lost bladder control chasing an answer, and the disease itself becomes the more likely explanation to pursue further.
Agreed: switch from oxybutynin to mirabegron, repeat neuropsychological testing at 8 weeks to see whether the word-finding difficulty improves.
Not agreed: the neurologist remains genuinely uncertain whether 8 weeks is long enough to see a real change if anticholinergic burden is the actual cause, given how gradually such effects are described in the older-population literature this case can't directly borrow from — the team agreed to extend the follow-up window rather than conclude anything definitively at 8 weeks if the picture is still unclear.